Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
siRNA
Biotech
Silence loses Mallinckrodt collab, wins in cardiovascular ph. 2
Silence Therapeutics used its full-year earnings results this morning to unveil a phase 2 win—but also the loss of one of its partnerships.
James Waldron
Mar 13, 2024 8:54am
Boehringer bets $2B in biobucks on siRNA treatments for MASH
Jan 3, 2024 6:00am
ADARx preps 3rd clinical program and mulls IPO
Oct 3, 2023 10:55am
RNA biotech ADARx hauls in healthy $200M series C
Aug 9, 2023 10:17am
Aligos culls another hep B asset over inconclusive efficacy data
Aug 4, 2023 7:27am
Agios pays $17.5M for Alnylam's siRNA blood disease program
Aug 3, 2023 8:40am